07:00 , Apr 15, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Cancer Farnesyl transferase; geranylgeranyltransferase I (PGGT1B; GGTase I) A study in mice suggests that antagonizing both farnesyl transferase and GGTase I could help treat...
07:00 , May 11, 2009 |  BC Week In Review  |  Clinical News

GGTI-2418: Phase I started

Tigris began an open-label, dose-escalation, U.S. Phase I trial to evaluate intravenous GGTI-2418 in 25-40 patients. Tigris has exclusive, worldwide rights to the compound from the University of South Florida (Tampa, Fla.) and Yale University...
07:00 , Mar 9, 2009 |  BC Week In Review  |  Clinical News

GGTI-2418: Phase I start

This quarter, Tigris will begin a dose-escalation, U.S. Phase I trial to evaluate GGTI-2418 in 25-40 patients. Tigris has exclusive, worldwide rights to the compound from the University of South Florida (Tampa, Fla.) and Yale...
07:00 , Jul 17, 2006 |  BC Week In Review  |  Company News

Tigris Pharmaceuticals, H. Lee Moffitt Cancer Center, University of South Florida, Yale University deal

Tigris Pharmaceuticals Inc. , New York, N.Y.   H. Lee Moffitt Cancer Center and Research Institute , Tampa, Fla.   University of South Florida , Tampa, Fla.   Yale University , New Haven, Conn.  ...
08:00 , Feb 25, 2002 |  BioCentury  |  Tools & Techniques

Displacing Ras

The Ras protein plays a pivotal role in the growth pathway in numerous cell types and overactivation of Ras is implicated in numerous cancers. Thus inhibition of Ras has attracted significant interest for its therapeutic...